Repligen Corporation (RGEN) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $115.28 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk).
Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four franchises: Filtration, Chromatography, Process Analytics, and Proteins. It sells consumables and hardware primarily to global biopharmaceutical companies, CDMOs, and... Read more
Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $115.28 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierXCell ATF® systems suppliers10-K Item 1A: 'only a small number of suppliers are currently qualified to supply materials for the XCell ATF® systems'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $115.28 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $107.21. Score 5.4/10, moderate confidence.
Take-profit target: $161.80 (+40.4% upside). Prior stop was $107.21. Stop-loss: $107.21.
Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk); Negative momentum.
Repligen Corporation trades at a P/E of 131.5 (forward 44.9). TrendMatrix value score: 5.2/10. Verdict: Sell.
28 analysts cover RGEN with a consensus score of 4.1/5. Average price target: $180.
What does Repligen Corporation do?Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four...
Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four franchises: Filtration, Chromatography, Process Analytics, and Proteins. It sells consumables and hardware primarily to global biopharmaceutical companies, CDMOs, and integrators worldwide. 39.5% of 2025 revenues were denominated in foreign currencies.